文献速递白血病造血干细胞移植与细胞治疗

年龄适配清髓性单倍体移植联合调节性与效应T细胞治疗急性髓系白血病

Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

本研究纳入50例中位年龄53岁的急性髓系白血病患者,采用年龄适配清髓性预处理(≤50岁用全身照射,51-65岁用全身骨髓/淋巴照射)后输注供者调节性T细胞、常规T细胞和纯化CD34+细胞,不做药物性GVHD预防。中位随访29个月,中重度cGVHD/无复发生存概率为75%(95%CI 71%-78%)。

要点

  • 年龄适配清髓性单倍体移植联合T细胞免疫治疗可行,全部患者实现供者型完全植入。
  • 仅1例发生中重度慢性GVHD,2例复发,中重度cGVHD/无复发生存概率达75%。

核心结论

  • 年龄适配清髓性单倍体移植联合调节性与常规T细胞过继免疫治疗,在50例AML患者中取得前所未有的cGVHD/无复发生存率。

研究设计与样本

  • 单臂研究,纳入50例AML患者,中位年龄53岁。
  • 预处理:≤50岁用全身照射,51-65岁用全身骨髓/淋巴照射,序贯塞替派、氟达拉滨和环磷酰胺。
  • 第-4天输注2×10^6/kg供者调节性T细胞,第-1天输注1×10^6/kg供者常规T细胞,第0天输注均值10.7×10^6±3.4×10^6/kg纯化CD34+造血祖细胞。
  • 移植后未给予药物性GVHD预防。

主要发现

  • 全部患者实现供者型完全植入。
  • 仅1例发生中重度慢性GVHD。
  • 10例发生非复发死亡,仅2例复发。
  • 中位随访29个月时,中重度cGVHD/无复发生存概率为75%(95%CI 71%-78%)。

临床怎么用

  • 该策略将年龄适配清髓性预处理与T细胞过继免疫治疗结合,移植后不做药物性GVHD预防。
  • 中重度cGVHD/无复发生存概率达75%,支持在AML单倍体移植中进一步评估该方案。

局限性

  • 单臂研究,样本量50例,中位随访29个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment in eradicating high-risk acute myeloid leukemia (AML). Here, we present data from a novel HLA-haploidentical HSCT protocol that addressed the 2 remaining major unmet medical needs: leukemia relapse and chronic graft-versus-host disease (cGVHD). Fifty AML patients were enrolled in the study. The conditioning regimen included total body irradiation for patients up to age 50 years and total marrow/lymphoid irradiation for patients age 51 to 65 years. Irradiation was followed by thiotepa, fludarabine, and cyclophosphamide. Patients received an infusion of 2 × 106/kg donor regulatory T cells on day -4 followed by 1 × 106/kg donor conventional T cells on day -1 and a mean of 10.7 × 106 ± 3.4 × 106/kgpurified CD34+ hematopoietic progenitor cells on day 0. No pharmacological GVHD prophylaxis was administered posttransplantation. Patients achieved full donor-type engraftment. Fifteen patients developed grade ≥2 acute GVHD (aGVHD). Twelve of the 15 patients with aGVHD were alive and no longer receiving immunosuppressive therapy. Moderate/severe cGVHD occurred in only 1 patient. Nonrelapse mortality occurred in 10 patients. Only 2 patients relapsed. Consequently, at a median follow-up of 29 months, the probability of moderate/severe cGVHD/relapse-free survival was 75% (95% confidence interval, 71%-78%). A novel HLA-haploidentical HSCT strategy that combines an age-adapted myeloablative conditioning regimen with regulatory and conventional T-cell adoptive immunotherapy resulted in an unprecedented cGVHD/relapse-free survival rate in 50 AML patients with a median age of 53 years. This trial was registered with the Umbria Region Institutional Review Board Public Registry as identification code 02/14 and public registry #2384/14 and at www.clinicaltrials.gov as #NCT03977103.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pierini A, Ruggeri L, Carotti A, et al. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. Blood Adv. 2021. PMID: 33646302. doi:10.1182/bloodadvances.2020003739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。